Heidelberg Pharma AG (FWB: HPHA) announced today that it will be participating in the following events.

Heidelberg Pharma specializes in oncology and is the first company to use and develop the active ingredient Amanitin for use in cancer therapies. To do this, the company uses its innovative ATAC technology (Antibody Targeted Amanitin Conjugates) and uses the toxin's biological mechanism of action as a new therapeutic principle.

HC Wainwright 22 nd Annual Global Investment Conference (virtual format)

Date: September 14 to 16 2020

Details of the presentation

ATACS: a unique new mode of action to fight cancer

Date: September 16, 2020 at 10:00 EDT / 16: 00 a.m. CEST

Speaker : Dr Jan Schmidt-Brand, Spokesman for the Management Board and CFO

Access to the presentation: https://wsw.com/webcast/hcw7/hpha.f/1773389

International HealthTech Innovation Days (mixed format)

Date: October 5-6 , 2020

Venue: The Peninsula Paris, Paris and virtual

Dr. Jan Schmidt-Brand will take part in the panel discussion 'Opportunities and challenges for Innovative Healthtech companies in Europe' on October 5, 2020 at 5:30 p.m.

About Heidelberg Pharma's proprietary ATAC technology

Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the effectiveness of small toxic molecules to fight cancer. ATACs (Antibody Targeted Amanitin Conjugates) are ADCs whose active ingredient consists of amatoxin molecules. Amatoxins are bicyclic peptides that occur naturally in the green leaf agaric. By binding to RNA polymerase II, they inhibit the transcription of the mRNA, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical studies, ATACs have shown a very high level of effectiveness, they overcome common resistance mechanisms and can also fight dormant tumor cells.

Contact:

Tel: +49 89 41 31 38-29

Email: investors[at]hdpharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire